Glyscend Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 16

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $10M

  • Investors
  • 13

Glyscend Therapeutics General Information

Description

Developer of gut-targeted polymer therapeutics designed for the treatment of metabolic indications such as type 2 diabetes and other chronic conditions. The company offers an orally administered drug, which is non-absorbed, gut-restricted duodenal exclusion therapy designed to replicate the metabolic effects of bariatric surgery with safety advantages, enabling patients to avoid invasive complications of surgeries and procedures.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1812 Ashland Avenue
  • Suite 110
  • Baltimore, MD 21205
  • United States
+1 (443)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 1812 Ashland Avenue
  • Suite 110
  • Baltimore, MD 21205
  • United States
+1 (443)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Glyscend Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 23-Mar-2023 $10M Completed Clinical Trials - Phase 2
7. Later Stage VC (Series A) 23-Oct-2019 Completed Clinical Trials - Phase 1
6. Grant 01-Aug-2019 Completed Clinical Trials - Phase 1
5. Grant 18-Sep-2017 Completed Clinical Trials - Phase 1
4. Grant 01-Jul-2015 Completed Clinical Trials - Phase 1
3. Accelerator/Incubator 05-May-2015 Completed Clinical Trials - Phase 1
2. Grant 01-Sep-2014 $165K Completed Startup
1. University Spin-Out 01-Jan-2014 Completed Startup
To view Glyscend Therapeutics’s complete valuation and funding history, request access »

Glyscend Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Glyscend Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Glyscend Therapeutics Patents

Glyscend Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220378886-A1 Methods of treating hyperoxaluria Inactive 06-Nov-2019
EP-4041740-A1 Benzoxaborole polymers and methods of use Inactive 20-Sep-2019
EP-4041740-A4 Benzoxaborole polymers and methods of use Inactive 20-Sep-2019
JP-2025019142-A Benzoxaborole polymers and methods of use Pending 20-Sep-2019
US-20220396651-A1 Benzoxaborole polymers and methods of use Inactive 20-Sep-2019 C08F230/06
To view Glyscend Therapeutics’s complete patent history, request access »

Glyscend Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Glyscend Therapeutics Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
Brandon Biocatalyst Venture Capital Minority
Brandon Capital Venture Capital Minority
Johnson & Johnson Innovation - JLABS Accelerator/Incubator Minority
Santé Ventures Venture Capital Minority
Breakout Labs Not-For-Profit Venture Capital Minority
You’re viewing 5 of 13 investors. Get the full list »

Glyscend Therapeutics FAQs

  • When was Glyscend Therapeutics founded?

    Glyscend Therapeutics was founded in 2014.

  • Where is Glyscend Therapeutics headquartered?

    Glyscend Therapeutics is headquartered in Baltimore, MD.

  • What is the size of Glyscend Therapeutics?

    Glyscend Therapeutics has 16 total employees.

  • What industry is Glyscend Therapeutics in?

    Glyscend Therapeutics’s primary industry is Drug Discovery.

  • Is Glyscend Therapeutics a private or public company?

    Glyscend Therapeutics is a Private company.

  • What is the current valuation of Glyscend Therapeutics?

    The current valuation of Glyscend Therapeutics is .

  • What is Glyscend Therapeutics’s current revenue?

    The current revenue for Glyscend Therapeutics is .

  • How much funding has Glyscend Therapeutics raised over time?

    Glyscend Therapeutics has raised $30.5M.

  • Who are Glyscend Therapeutics’s investors?

    Brandon Biocatalyst, Brandon Capital, Johnson & Johnson Innovation - JLABS, Santé Ventures, and Breakout Labs are 5 of 13 investors who have invested in Glyscend Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process